Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
暂无分享,去创建一个
Alison P. Klein | Drew M. Pardoll | Haiying Xu | Janis M. Taube | Shuming Chen | Rajni Sharma | Robert A. Anders | J. Taube | A. Klein | Lieping Chen | D. Pardoll | S. Topalian | Rajni B. Sharma | R. Anders | T. McMiller | Haiying Xu | Shuming Chen | Lieping Chen | Suzanne L. Topalian | Geoffrey D. Young | Tracee L. McMiller
[1] J. Bluestone,et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.
[2] H. V. van Boven,et al. Overall survival and PD‐L1 expression in metastasized malignant melanoma , 2011, Cancer.
[3] K. Heeg,et al. PD‐L1 expression on tolerogenic APCs is controlled by STAT‐3 , 2011, European journal of immunology.
[4] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[5] M. Mihm,et al. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[6] J. Cheville,et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. , 2006, Cancer research.
[7] G. Zhu,et al. B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. , 2004, Immunity.
[8] J. Fridlyand,et al. Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.
[9] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[10] G. Freeman,et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.
[11] George Coukos,et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.
[12] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Qattan,et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. , 2006, Neoplasia.
[15] George Coukos,et al. Cancer immunotherapy comes of age , 2011, Nature.
[16] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[17] D. Pinkel,et al. Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[19] G. Freeman,et al. Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1 , 2003, The Journal of Immunology.
[20] N. Xu,et al. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. , 2006, Acta histochemica.
[21] Z. Trajanoski,et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.
[22] G. Zhu,et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.
[23] P. Schlag,et al. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. , 2001, Cancer research.
[24] 日野 亮介. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma , 2010 .
[25] Natale Cascinelli,et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.
[26] N. Pavlidis,et al. Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. , 2011, Critical reviews in oncology/hematology.
[27] T. Gajewski,et al. Gene Signature in Melanoma Associated With Clinical Activity: A Potential Clue to Unlock Cancer Immunotherapy , 2010, Cancer journal.
[28] David C. Smith,et al. Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. , 2010 .
[29] G. Freeman,et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.
[30] T. Okazaki,et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. , 2001, Science.
[31] A. Feldman,et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] A. Fauci,et al. The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands , 2008, The Journal of Immunology.
[33] G. Freeman,et al. Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses , 2003, European journal of immunology.
[34] N. Mitsiades,et al. Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. , 1999, The Journal of clinical endocrinology and metabolism.
[35] R. Schreiber,et al. Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.
[36] J. Cheville,et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[37] Yoshimasa Tanaka,et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[38] T. Curiel,et al. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.
[39] Rui-Ru Ji,et al. An immune-active tumor microenvironment favors clinical response to ipilimumab , 2012, Cancer Immunology, Immunotherapy.
[40] M. Gordon. Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4 , 2008 .
[41] H. Griesser,et al. Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.
[42] M. Azuma,et al. Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer , 2005, Clinical Cancer Research.
[43] S. H. van der Burg,et al. Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma , 2009, Clinical Cancer Research.
[44] G. Zhu,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[45] T. Honjo,et al. Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.
[46] Expression of Programmed Death 1 Ligands by Murine T Cells and APC1 , 2002, The Journal of Immunology.
[47] J. Cheville,et al. Costimulatory B 7-H 1 in renal cell carcinoma patients : Indicator of tumor aggressiveness and potential therapeutic target , 2004 .
[48] M. Bonneville,et al. Comprehensive analysis of the frequency of recognition of melanoma‐associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy , 2001, European journal of immunology.
[49] J. Cheville,et al. Mononuclear cell infiltration in clear‐cell renal cell carcinoma independently predicts patient survival , 2006, Cancer.
[50] T. Oshikiri,et al. CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma , 2004, Pancreas.
[51] P. Mischel,et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.
[52] Y. Soini,et al. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[53] R. Thompson,et al. Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy , 2007, Clinical Cancer Research.
[54] S. Steinberg,et al. Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade , 2007, Clinical Cancer Research.
[55] Lieping Chen,et al. The new B7s: playing a pivotal role in tumor immunity. , 2007, Journal of immunotherapy.
[56] Lieping Chen,et al. Inhibitory B7-family molecules in the tumour microenvironment , 2008, Nature Reviews Immunology.